Posted by Michael Wonder on 12 Jul 2023
Lorlatinib for the treatment of adults with advanced ALK positive non-small-cell lung cancer
12 July 2023 - NICE has published final evidence-based recommendations on the use of lorlatinib (Lorviqua) for the treatment of adults with advanced ALK positive non-small-cell lung cancer.
Lorlatinib is not recommended for the treatment of adults with advanced anaplastic lymphoma kinase (ALK) positive non-small-cell lung cancer who have not been treated with an ALK inhibitor.
